Boulder Peptide Symposium 2016
APL-2 And Complement Inhibition; A Potential Treatment Of PNH And Other Complement-Mediated Diseases
The following information is available for educational purposes only. The information is not to be re-purposed or re-used in its current form or presentation for any personal or professional use. Apellis reserves the right to withdraw, modify or change the information that is available on this website at any time.